Planetary Health
Mental Health
AMR
Caregiver
Pharmacy
COVID-19
Global Health Education
Ebola
Natural Hazards
Conflict
Zika
TB
Cholera
Leprosy
HIV
Polio
Rapid Response
Refugee
Disability
Specific Hazards
Social Ethics
MEDBOX is an innovative online library aimed at improving the quality of healthcare in humanitarian action, worldwide.
MEDBOX is an independent internet platform supported by international agencies and scientific institutions active in humanitarian assistance, development and health work worldwide. MEDBOX collates the increasing number of professional guidelines, textbooks and practical documents on health action available online today and brings these into the hands of humanitarian aid and health workers: when they need it, where they need it.
MEDBOX is still under development! We are keen to receiving more documents, training materials and presentations relevant to improve the quality of health action! Your feedback is valuable to us, so do get in touch if you have something you'd like to share with us to improve on, and maximise, our collaborative space. Do send your comments to: news@medbox.org
MEDBOX. Capacity building and quality assurance through innovation.
For more information please go to our section of annual report here
The MEDBOX Team has started a new feature publishing Issue Briefs with different topics.
FILTER BY LANGUAGE
FILTER BY COUNTRY
RESULTS/PAGE
LIST TYPE
2 April 2022
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below. This document has been updated: version 15 March 2022. The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses ... more
The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.
COVAXINTM, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility. The vaccine received DCGI approval for Phase I & II Human Clinical Trials and the trials commenced across India from July, 2020. After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of COVAXINTM, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India ... more
6 records
View PDF
Download
Add to my MEDBOX
